Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

About this update from Cascade Copper Corp.

[{"type":"text","content":"\n\n\n\nSEATTLE, WA, May 30 /CNW/ - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY)\n(the "Company") today announced that data from clinical trials for three of\nthe Company's product candidates were presented at the American Society of\nClinical Oncology (ASCO) Annual Meeting on May 30, 2009 in Orlando, Florida.\nThe presentations included long-term safety data from the Phase 2b trial of\nStimuvax(R) in patients with stage IIIB/IV non-small cell lung cancer,\npreliminary results from the Phase 1 trial of the phosphoinositide-3-kinase\n(PI-3 kinase) inhibitor PX-866 in patients with advanced malignancy, and final\nresults from two Phase 1b trials of the thioredoxin inhibitor PX-12 in\nadvanced cancer patients.\n\n\nStimuvax\n\n\nData concerning the long-term safety of Stimuvax (BLP25 liposomal\nvaccine) were presented by Dr. Charles Butts, Cross Cancer Institute,\nEdmonton, Alberta. Sixteen patients who received Stimuvax for between 2 and\n8.2 years as part of the Phase 2b trial in patients with stage IIIb/IV\nnon-small cell lung cancer (NSCLC) were studied. Ten of these patients have\nbeen treated for more than five years, and eight continue to receive therapy\nwith Stimuvax. Prolonged treatment with Stimuvax was well-tolerated in this\ntrial. The most common treatment-related adverse events were injection site\nreactions, which tended to diminish after the first year of treatment. There\nwas no evidence of autoimmune reactions with prolonged use.\n\n\n"We are very pleased that this group of long-term survivors with advanced\nNSCLC has been able to continue to receive Stimuvax with apparent safety for\nup to eight years," said Robert L. Kirkman, M.D., President and Chief\nExecutive Officer of Oncothyreon. "These patients were treated as part of the\nrandomized Phase 2b trial conducted by Oncothyreon, in which the subset of\npatients with Stage IIIb locoregional disease who received Stimuvax had a\nmedian survival of 30.6 months compared with 13.3 months for similar patients\nwho did not receive the vaccine, a difference of 17.3 months. Long-term\nfollow-up of these patients was conducted by Merck KGaA of Darmstadt, Germany,\nwhich assumed responsibility for the clinical development of Stimuvax in\n2007."\n\n\nMerck KGaA is conducting a global Phase 3 trial of Stimuvax known as\nSTART (Stimulating Targete...

More updates from Cascade Copper Corp.